BlueRock Therapeutics IPO

BlueRock Therapeutics is an engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases with a platform that harnesses the power of cells for new medicines across neurology, cardiology and autoimmune indications.

Register for Details

For more details on financing and valuation for BlueRock Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about BlueRock Therapeutics

Forge green plus iconForge green minus icon

What is BlueRock Therapeutics funding to date?

BlueRock Therapeutics has raised $225MM to date.
Forge green plus iconForge green minus icon

When was BlueRock Therapeutics founded?

BlueRock Therapeutics was founded in 2016.
Updated on: Jun 12, 2022


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.